ANECAINE CREAM 2,5% Lidocaine - 2,5% Prilocaine

ANECAINE CREAM is an anesthetic cream used in cosmetic and medical applications. Product manufactured by Seer Pharm (Korea).

Purpose of product use

Surface anesthesia of the skin when inserting a needle or performing superficial surgical procedures
Surface anesthesia of genital mucosa (e.g. before removal of condyloma)
Superficial anesthesia of leg ulcers prior to cleaning or superficial surgery (e.g., removal of fibrin, pus, and dead areas)

How to use ANECAINE CREAM?

Adult

1. Skin: After applying this medicine, cover with sealing tape. The seal on the application area should usually be maintained for 1-3 hours and the effect will last at least 1 hour after the sealing tape is removed.

When inserting a needle (e.g., intravenous intubation, blood collection), apply 2 g of this drug for at least 1 hour and up to 5 hours.
During superficial surgical minor surgery (e.g. extraction of a continuous tumor), apply 1.5 -2g/10㎠ of this drug for 1 hour.
When major superficial surgery (e.g. ruptured skin graft), apply 1.5 -2g/10㎠ of this drug for a minimum of 2 hours and a maximum of 5 hours.

2. Genital mucosa: When removing condyloma, apply 10g of this drug to the treatment area for 5-10 minutes, then remove this drug and begin the procedure immediately.

3. Leg ulcer: After applying this medicine, cover it with sealing tape. Use the opened tube once and discard any remaining pictures after each operation. Apply 1 -2g/10㎠ for at least 30 minutes each treatment.

Do not exceed 10g per hour. For leg ulcers with tissues that are difficult to apply, the application time can be extended to 60 minutes, and the ulcer should be cleaned within 10 minutes after removing the cream.

Infants aged 3 to 12 months

Total amount: 2g, application area not exceeding 16㎠

Precautions for use

Warning methemoglobinemia

Cases of methemoglobinemia have been reported in association with local anesthetic use. All patients are at risk for methemoglobinemia, but those with glucose-6-phosphate anhydrase deficiency, congenital or idiopathic.
Patients with methemoglobinemia, heart or lung damage, infants less than 6 months of age, and patients concurrently exposed to oxidizing agents or metabolites of these drugs are more susceptible to developing clinical symptoms of methemoglobinemia. For patients like this
Close monitoring for signs and symptoms of methemoglobinemia is recommended when using minor anesthetics.

Signs of methemoglobinemia may occur immediately or several hours after exposure to the drug and are characterized by bluish skin discoloration and/or abnormal blood staining. The methemoglobin level is
To avoid more serious central nervous system and cardiovascular abnormalities (seizures, coma, arrhythmia, death, etc.), administration of this drug and other oxidizing agents should be discontinued and immediate treatment should be administered.
all. Depending on the severity of symptoms and signs, patients may respond to supportive care (i.e., oxygen therapy, hydration). More severe clinical manifestations may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.

Do not administer to the following patients

Patients with hypersensitivity to the ingredients of this drug or other amide-based local anesthetics
Patients with wounds, mucous membranes, contact dermatitis or atopic dermatitis
Infants under 3 months of age
Infants under 12 months of age receiving methemoglobinemia-inducing drugs (sulfonamides, etc.)
Premature baby born before 37 weeks of pregnancy

Administer with caution to the following patients

Patients with anemia, methemoglobinemia, or medications that may cause these symptoms
Weak people, elderly people, patients with acute diseases
Patients with severe liver disease
This medicine contains propylene glycol, so administer it with caution to patients who are hypersensitive to this ingredient or have a history of allergy.

Side effects

Local reaction: Local paleness, redness, swelling, and rarely itching and initial burning may occur.
Others: Allergic and anaphylactic reactions such as hives, vasogenic edema, bronchospasm, and shock may occur.
Methemoglobinemia has rarely occurred in children. In particular, isolated reactions such as purpura or petechiae rarely occurred when applied long-term to children with atopic dermatitis or dermatitis.
all. Accidental contact with eyes may cause corneal irritation.

General precautions

It is known that parenteral administration of prilocaine causes methemoglobinemia.
When this drug is used in adults at the recommended dose, the formation of methemoglobin due to the metabolite of prilocaine is generally not clinically significant. However, glucose-6-phosphate dehydrogenase
Some patients, such as those with bovine deficiency or congenital or idiopathic methemoglobinemia, are more susceptible to drug-induced methemoglobinemia.
There is little risk of systemic toxicity at the usual dose of this drug, but if signs of toxicity appear, symptoms similar to those after administration of other local anesthetics are expected. (Symptoms of central nervous system excitement,
In some cases, central nervous system depression and myocardial depression) This drug is absorbed systemically from the skin at a slow rate, so caution should be exercised when treating patients who show signs of toxicity for several hours must be observed.
When injecting a live vaccine such as BCG subcutaneously, do not use it because interaction between the main ingredient of this drug and the vaccine cannot be ruled out.
If you have atopic dermatitis, the application time should be reduced (15 -30 minutes).
In clinical trials, this drug did not show pain relief during heel capillary blood collection in newborns.
Patients taking lidocaine and Class III anti-arrhythmic drugs (e.g. amiodarone) together should be observed carefully as the effects on the heart of the two drugs may be additive, and ECG monitoring should be considered.